Shaping livestock solutions
“Huvepharma®’s strategic investments in the 2020s are directed towards improving energy efficiencies and renewable energy installations. Over 500 million euros has been invested to improve energy performance in manufacturing, reduce our reliance on fossil fuels and make good on our commitment to be carbon neutral by 2030.”
Mr Kiril Domuschiev President
Huvepharma®’s product portfolio is derived from fermentation. Its manufacturing facilities have over 60 years’ of fermentation expertise.
The science of fermentation is known as zymology and is the process of releasing energy from a carbohydrate without oxygen It is a type of anaerobic respiration or respiration under anaerobic conditions with no external electron acceptor.
In Huvepharma®’s product production, fermentation is the use of microorganisms in an industrial environment and under controlled conditions to produce useful products.
Fermentation starts with a pure culture of the micro organism in the laboratory The preparation of ‘seed material’ in flasks follows which is then transferred to small fermenters.
During the upscaling phase, the content of the inoculators is transferred into large fermenters. Once the energy intensive fermentation phase is complete, the fermentation broth is processed downstream. Downstream processes include filtering, spray drying and purification. The active product ingredient (API) is then ready for further processing into the finished forms which are used to shape livestock solutions.
Manufacturing process
1
Seed material Finished forms
The Manufacturing Process
Four critical utilities are required for the manufacturing process, which is energy- and water intensive. Reducing the carbon footprint of these critical utilities is central to Huvepharma®’s ambitions.
Steam Compressed air Electricity Water
Huvepharma® is mindful of protecting the environment and reducing its reliance on fossil fuels and water, both finite resources.
2
Huvepharma® is proud of its manufacturing facilities in Europe and, in line with the European Green Deal, Huvepharma® is improving its energy efficiencies and performance and reducing its environmental impact at its manufacturing sites.
Significant investments in renewable energy installations will ensure that it is self-reliant and autonomous for its energy needs.
Coupled with Huvepharma®’s ‘Strain to Shelf’ philosophy, autonomy for both energy and API production is assured.
3
Huvepharma®’s manufacturing facilities will be carbon neutral by 2030
The Pathway to Carbon-Neutral Production
4
Huvepharma®’s pathway to carbon-neutral production comprises significant investments of over €500 million in renewable energy installations and in improving energy efficiencies and performance. Protecting the environment remains at the core of its manufacturing activities.
Huvepharma®’s investments in renewable energy installations comprise of nearly €270 million whilst investments in improving energy efficiencies and performance total €270 million.
5
Investments in renewable energy installations €269 million 2024-2030 €50 million 17MW 2024-2030 €80 million 300MW 2023 €70 million 200MW 2023-2030 €19 million Green hydrogen plant 2022 €35 million 75MW 2021 €15 million 25MW Renewable Energy Installations Solar Panel Installations Geothermal Plant
Solar panel installations
2021 Dec 2021 Dec 2022 June 2023 Dec 2023 By 2030
Project Initiation 25 MW total capacity
75 MW total capacity
175 MW total capacity
200 MW total capacity
300 MW* total capacity
Solar power is the conversion of energy from sunlight into electricity. 300MW is sufficient for 300’000 households and requires ~300 hectares.
Green hydrogen production
Huvepharma®’s investment of €19 million in green hydrogen production takes place through water electrolysis using solar generated electricity. 10MW of solar energy will be used to produce green hydrogen. This green hydrogen will be used in the steam boilers (30% reduction of emissions) and is emission-free at the point of use. Green hydrogen
7
Solar panel installations
Geothermal plant
Huvepharma®’s investment of €50 million (2024-2030) in geothermal energy will produce 17MW of energy. The plant will be operational in 2026.
Geothermal plant
Renewable
9
Huvepharma® will be certified as carbon neutral based on the installed capacity of renewable energy. Manufacturing process Electricity
plant Solar panel installations Green hydrogen 317 MW installed capacity 45-47 MW requirement
energy inputs
Geothermal
Energy Efficiencies and Performance
10
Investments in improving energy efficiencies and performance
– present €100 million on energy performance and efficiency projects including: 2019 €150 New fermentation plant 2017 €20 million Incinerator plants Insulation projects Ventilation projects Water cooling plant €270 million
1997
Energy efficiency projects
With every investment, Huvepharma® is demonstrably reducing its carbon footprint. Even before “sustainability” became a part of our everyday vocabulary, Huvepharma® implemented innovative technologies in equipment and supporting installations to lower its reliance on finite energy resources. These investments allow Huvepharma® to be more resilient regarding volatile fossil fuel prices and ensure that the environment remains protected for future generations.
Incinerator plants to promote a circular economy
Water cooling tower
Insulation projects
Ventilation projects (natural ventilation and mechanical air handling units)
Energy-efficient lighting systems in operation in all Huvepharma® facilities The fermentation facility, commissioned in 2019 and one of the largest in Europe, is 15% more efficient than a traditional plant
Water cooling tower
Incinerator
11
The
Steam is a critical utility and essential for the fermentation process. Huvepharma®’s circular economy minimises the use of resource inputs and the creation of waste, pollution and carbon emissions.
Waste from paper, plastic, polythene, biomass, the local community, downstream processing and waste water pulp
12
incinerator plant and the circular economy
Incinerator plant: purification and 24-hour monitoring of exhaust air
30%
Steam Manufacturing process Incinerator Waste requirements are produced in its circular economy through heat recovery
of Huvepharma®’s steam
13 The water cooling tower for cooling is recycled in the water cooling tower 85-90% of Huvepharma®’s water Manufacturing process Water cooling tower
Environmental Protection
Environmental protection projects
Over the past 15 years, Huvepharma® has invested in supporting installations which minimise the impact on the environment. These investments have a societal, as well as environmental, benefit.
Ozone treatment plant uses 70% less energy whilst doubling output
Silos for raw material storage to reduce packaging and waste
Air exhaust treatment facilities
Wastewater treatment facilities
Recycling facilities in place in all Huvepharma® premises
Exhaust air treatment
Societal benefits
Noise and odour reduction
Local waste collection for incineration reducing landfill Wastewater treatment plant
14
Green from Strain to Shelf
Huvepharma® is proud of its commitment to carbon-neutral production by 2030.
With its significant investments in renewable energy installations and in improving energy efficiencies and performance, Huvepharma® is confident that it will achieve its sustainability targets. Reducing the carbon footprint of the four critical utilities of the fermentation process (steam, water, compressed air and electricity) is central to Huvepharma®’s ambitions.
Huvepharma®’s products reduce the environmental impact of livestock on farm. Combined with the reduction of greenhouse gases in the manufacturing process, Huvepharma® is leading the way in sustainably shaping livestock solutions.
15